Trial Profile
PET Measures of CSF Clearance in Preclinical Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Oct 2022
Price :
$35
*
At a glance
- Drugs Florquinitau F18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- 18 Oct 2022 Status changed from recruiting to completed.
- 29 Apr 2022 Planned End Date changed from 1 Jun 2022 to 31 Aug 2022.
- 29 Apr 2022 Planned primary completion date changed from 1 Jun 2022 to 31 Aug 2022.